Charles Riv Labs Intl Inc Stock Price, News & Analysis

Charles River Laboratories (NYSE:CRL) announced plans to explore a strategic partnership with BioTech Social Inc. (BSI) to integrate crowdfunding capabilities into their Incubator (CIP) and Accelerator (CAP) Programs. The collaboration would enable early-stage cell and gene therapy developers to raise up to $5 million annually through BSI's BioTech Funding Portal.

The partnership aims to help biotech companies bridge the funding 'valley of death' by connecting them with non-accredited investors. This initiative builds upon Charles River's 2024-established CIP and CAP programs, which provide regulatory expertise, laboratory space, and equipment access. The companies plan to evaluate applications for the next cohort in conjunction with the upcoming European Cell and Gene Therapy Summit in September 2025.

Charles River Laboratories (NYSE: CRL) has entered into a strategic CDMO agreement with Elly's Team, a parent-led foundation focused on developing treatments for NEDAMSS, an ultra-rare genetic disorder. The collaboration leverages Charles River's Cell and Gene Therapy Accelerator Program to manufacture critical materials for Phase I clinical trials.

The partnership has already achieved significant success, with Elly becoming the first patient to receive IRF2BPL gene replacement therapy on April 3, 2025. The treatment received FDA approval in March 2025, just 13 months after diagnosis. Elly's Team utilized Charles River's eXpDNA™ platform and AAV Rep/Cap plasmids, reducing manufacturing efforts by up to 66 percent.

NEDAMSS, caused by IRF2BPL gene mutations, affects fewer than 150 cases worldwide and impacts motor skills, speech, eating, eyesight, and can cause seizures.

Charles River Laboratories (NYSE:CRL) has announced its second-quarter 2025 earnings release schedule. The company will release its financial results on Wednesday, August 6th, 2025, before market opening. A conference call to discuss the results will be held the same day at 9:00 a.m. ET.

Investors can access the live webcast through the company's Investor Relations website at ir.criver.com, where a replay will also be available after the call.

Charles River Laboratories (NYSE: CRL) has launched a recycling program for Endosafe bacterial endotoxin testing cartridges in partnership with TerraCycle. The program, starting July 2025, allows labs to recycle single-use plastic cartridges used in water testing, which represents 70% of global bacterial endotoxin tests. Available in the US and select European countries, customers will receive Zero Waste Boxes to collect and return used cartridges, which will be recycled into raw materials for new products. This initiative builds on Charles River's previous sustainability achievements, including their Endosafe Cartridge Technology that reduced horseshoe crab-derived LAL usage by 95%, and their Endosafe Trillium recombinant cascade reagent.

Charles River Laboratories (NYSE: CRL) has announced its participation in two major healthcare conferences: the William Blair 45th Annual Growth Stock Conference on June 3rd at 11:00 a.m. ET and the Jefferies Global Healthcare Conference on June 4th at 10:30 a.m. ET. During these presentations, management will discuss the company's strategic direction, business developments, and recent industry trends. Both presentations will be accessible via live webcast through the company's Investor Relations website at ir.criver.com, with replay options available for approximately two weeks after each event.

Charles River Laboratories (NYSE: CRL) and CHDI Foundation have announced the extension of their 20-year drug discovery partnership focused on developing treatments for Huntington's disease (HD). The collaboration, which began in 2005, will expand across Charles River's global network and integrate more deeply with CHDI's programs.

The extended partnership encompasses comprehensive services including integrated chemistry, biology, ADME for drug discovery, stem cell research, high-throughput screening, computational chemistry, pharmacology, and biomarker discovery. Over their collaboration, the partnership has yielded 15 composition of matter patent applications and supported research with more than 50 pharma and biotech companies.

The agreement includes data sharing with Charles River's learning algorithms, contributing to the industry's largest dataset while maintaining data protection standards.

Charles River Laboratories (NYSE: CRL) announced its upcoming presentation at the Bank of America 2025 Health Care Conference scheduled for Wednesday, May 14th at 8:40 a.m. PT (11:40 a.m. ET). During the presentation, management will discuss the company's strategic focus, business developments, and recent trends. The presentation will be accessible via live webcast through the Investor Relations section of Charles River's website at ir.criver.com. A replay will be available for at least two weeks after the event.

Charles River Laboratories (NYSE: CRL) reported Q1 2025 results with revenue of $984.2 million, down 2.7% from Q1 2024. The company posted GAAP EPS of $0.50 and non-GAAP EPS of $2.34, with the latter showing a 3.1% increase. Despite revenue declines across all segments, CRL saw improved DSA booking activity reaching its highest level in two years. The company repurchased $350 million of common stock in Q1 and increased its 2025 guidance, now projecting organic revenue decline of (4.5)% to (2.5)% and non-GAAP EPS of $9.30-$9.80. The results reflect ongoing market uncertainties but show signs of demand stabilization, particularly in the DSA segment.

Charles River Laboratories (NYSE: CRL) announced significant governance updates and a strategic review to enhance stockholder value. The company will appoint four new directors - Steven Barg, Abe Ceesay, Mark Enyedy, and Paul Graves - while four existing directors will not seek re-election at the 2025 Annual Meeting. The board will be restructured to include eleven directors, with nine being independent.

The company has entered into a Cooperation Agreement with Elliott Investment Management, its largest investor. A Strategic Planning and Capital Allocation Committee will conduct a comprehensive review of Charles River's business and prospects to enhance long-term stockholder value. Additionally, the board will establish a New Approach Methodologies and Science Committee through the merger of existing committees.